Intravitreal Dexamethasone Implant in Anti-Vascular Endothelial Growth Factor Pretreated Diabetic Macular Edema-A Swiss Cohort Study

Macular Diseases

Intravitreal anti-vascular endothelial growth factor injections and risks of stroke in patients with neovascular age-related macular degeneration-A registry-based cohort study

Acta Ophthalmol

Falemban AH, Söderberg-Löfdal K, Jonsson F, Almlöf-Sarman S, von Euler M, Westborg I

doi: 10.1111/aos.17534

Macular Diseases

How intravitreal anti-vascular endothelial growth factor initial dosing impacts patient outcomes in diabetic macular oedema

BMC Ophthalmol

Singh RP, Tabano D, Kuo BL, LaPrise A, Leng T, Kim E, Hatfield M, Garmo V

doi: 10.1186/s12886-024-03797-9

Macular Diseases

Real-World Outcomes of Different Types of Treatment for Diabetic Macular Edema Before and After Approval of Anti-Vascular Endothelium Growth Factor Agents

J Clin Med

Sugimoto M, Chujo S, Kato K, Shimura M, Kitano S, Kusuhara S, Terasaki H, Kondo M, Writing Committee Of Japan-Clinical Retina Study Group J-Crest

doi: 10.3390/jcm13237336

Further Publications

Comparison of Renal Adverse Events Between Intravitreal Anti-Vascular Endothelial Growth Factor Agents: A Meta-Analysis

Am J Ophthalmol

Huang RS, Balas M, Jhaveri A, Popovic MM, Kertes PJ, Muni RH

doi: 10.1016/j.ajo.2024.12.023

Retinal DiseasesSurgery and Intervention

Anti-vascular endothelial growth factor injections vs panretinal photocoagulation laser therapy for proliferative diabetic retinopathy - A systematic review and meta-analysis

Ophthalmol Retina

Macaron MM, Al Sabbakh N, Shami MZ, Akrobetu D, Bourdakos NE, Abdulsalam FAM, Nakanishi H, Than CA, Bakri SJ

doi: 10.1016/j.oret.2024.08.004

Macular DiseasesSurgery and Intervention

Submacular Hemorrhage Rates Following Anti-Vascular Endothelial Growth Factor Injections for Exudative Age-Related Macular Degeneration

Am J Ophthalmol

Kaufmann GT, Boucher N, Sharma C, Aggarwal N, Starr MR

doi: 10.1016/j.ajo.2024.10.017

Macular DiseasesRetinal Diseases

Fight Retinal Blindness SPAIN. Report 3: clinical outcomes of vascular endothelial growth factor inhibitors in low vision eyes with neovascular age-related macular degeneration. A national database study

Eye (Lond)

Puzo M, Calvo-Perez P, Bartol-Puyal F, Sanchez-Monroy J, Martin-Pinardel R, Parrado-Carrillo A, Moll-Udina A, Bernal-Morales C, Sanchez-Vela L, Sararols-Ramsay L, Garay-Aramburu G, Arruabarrena C, García-Arumí J, Abraldes M, Ruiz-Moreno JM, Valldeperas X, Velázquez-Villoria D, Escobar-Barranco JJ, Gallego-Pinazo R, Figueroa MS, Figueras-Roca M, Barthelmes D, Gillies MC, Casaroli-Marano RP, Zarranz-Ventura J, from the writing committee of the Fight Retinal Blindness Spain (FRB! Spain) Users Group

doi: 10.1038/s41433-024-03322-8

Macular Diseases

Fluid fluctuations assessed with artificial intelligence during the maintenance phase impact anti-vascular endothelial growth factor visual outcomes in a multicentre, routine clinical care national age-related macular degeneration database

Br J Ophthalmol

Martin-Pinardel R, Izquierdo-Serra J, Bernal-Morales C, De Zanet S, Garay-Aramburu G, Puzo M, Arruabarrena C, Sararols L, Abraldes M, Broc L, Escobar-Barranco JJ, Figueroa M, Zapata MA, Ruiz-Moreno JM, Parrado-Carrillo A, Moll-Udina A, Alforja S, Figueras-Roca M, Gómez-Baldó L, Ciller C, Apostolopoulos S, Mishchuk A, Casaroli-Marano RP, Zarranz-Ventura J, from the FRB SPAIN-IMAGE Project Investigators

doi: 10.1136/bjo-2024-325615

Macular Diseases

Biomarkers of risk of switching to dexamethasone implant for the treatment of diabetic macular oedema in real clinical practice: a multicentric study

Br J Ophthalmol

Ruiz-Medrano J, Udaondo Mirete P, Fernández-Jiménez M, Asencio-Duran M, Fernández-Vigo JI, Medina-Baena M, Flores-Moreno I, Pareja-Esteban J, Touhami S, Giocanti-Aurégan A, Cicinelli MV, Loewenstein A, Ruiz-Moreno JM

doi: 10.1136/bjo-2024-325665

Related content

Intravitreal anti-vascular endothelial growth factor injections and risks of stroke in patients with neovascular age-related macular degeneration-A registry-based cohort study

How intravitreal anti-vascular endothelial growth factor initial dosing impacts patient outcomes in diabetic macular oedema

Real-World Outcomes of Different Types of Treatment for Diabetic Macular Edema Before and After Approval of Anti-Vascular Endothelium Growth Factor Agents

Comparison of Renal Adverse Events Between Intravitreal Anti-Vascular Endothelial Growth Factor Agents: A Meta-Analysis

Anti-vascular endothelial growth factor injections vs panretinal photocoagulation laser therapy for proliferative diabetic retinopathy - A systematic review and meta-analysis

Submacular Hemorrhage Rates Following Anti-Vascular Endothelial Growth Factor Injections for Exudative Age-Related Macular Degeneration

Fight Retinal Blindness SPAIN. Report 3: clinical outcomes of vascular endothelial growth factor inhibitors in low vision eyes with neovascular age-related macular degeneration. A national database study

Fluid fluctuations assessed with artificial intelligence during the maintenance phase impact anti-vascular endothelial growth factor visual outcomes in a multicentre, routine clinical care national age-related macular degeneration database

Biomarkers of risk of switching to dexamethasone implant for the treatment of diabetic macular oedema in real clinical practice: a multicentric study